Providers/Grant Support
This activity is supported by an educational grant from Sun Pharmaceutical Industries Ltd.
Credits Available
- Physicians — maximum of 0.5 AMA PRA Category 1 CreditsTM
All other healthcare professionals completing this course will be issued a statement of participation
Target Audience
This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.
Program Overview
In this short program at the 2025 Fall Clinical Dermatology Conference®, experts Dr. Rigel and Dr. Schlesinger explore the expanding therapeutic landscape for cutaneous squamous cell carcinoma (cSCC) and review an emerging mechanism targeting PD-L1. Don’t miss this opportunity to learn about the new checkpoint inhibitor in the cSCC space!
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Compare programmed cell death protein-1 (PD-1) inhibitors and programmed cell death ligand-1 (PD-L1) inhibitors for cutaneous squamous cell carcinoma (cSCC) based on their mechanism of action
- Review the latest clinical efficacy and safety data for PD-1 and PD-L1 inhibitors in the treatment of advanced cSCC
Faculty
Darrell Rigel, MD, MS
Clinical Professor of Dermatology, New York University, Grossman School of Medicine, New York, NY
Adjunct Professor, UT Southwestern Medical School
Consultant Dermatologist, Cooper Clinic, Dallas, TX
Todd Schlesinger, MD
Director, Clinical Research Center of the Carolinas, Charleston, SC
Clinical Assistant Professor of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, DC
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada, Reno School of Medicine and CMEsquared. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
The University of Nevada, Reno School of Medicine designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflict of Interest
Darrell S. Rigel, MD, MS
Advisory Board: Castle Biosciences, Almirall
Grant/Research Support: Castle Biosciences
Consultant: Castle Biosciences
Speakers’ Bureau Honoraria: Beiersdorf, Castle Biosciences, Almirall, DermTech
Todd E. Schlesinger, MD
No relevant financial relationships with any Ineligible Company in the past 24 months.
The University of Nevada, Reno School of Medicine discloses that all relevant conflicts have been satisfactorily mitigated.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be immediately available to the participant.
Disclosure of Unlabeled Use
The Institute requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Contact Information
For CME questions please contact: [email protected]